Skip to main content
Thyrogen® (thyrotropin alfa) for injection logo

Thyrogen® (thyrotropin alfa) for injection Helps Maintain Function


With Thyrogen, you can lower the impact to health-related quality of life (HRQoL) by allowing your patients to remain euthyroid during ablation and diagnostic testing.

SF-36 Health Survey Results in a Thyrogen Diagnostic Trial with 229 Patients.1

Quality of life differences in all eight groups was statistically significant between the Thyrogen and THW arms.

A bar chart comparing quality of life across eight groups during three phases: Pre-treatment, Thyrogen, and Withdrawal.

Thyrogen patients had significant benefits compared with THW2

In the HiLo Study2
Mallick U, et al
(438 evaluable patients)

Before ablation, patients receiving Thyrogen had clear benefits compared with patients undergoing THW in physical and social functioning, role limitations, and energy or fatigue (P<0.001 for most comparisons).

Mean difference in the Short Form (SF)-36 scores for the trial comparisons completed on the day of ablation, covering the time before ablation.

A bar chart comparing physical and social functioning between Thyrogen patients and THW patients.

Adapted from Mallick U, et al, 2012.

HiLo is a non-inferiority, parallel, open-label, randomized controlled factorial trial involving 438 patients. Patients were randomly assigned (1:1:1:1) to 30 mCi or 100 mCi ablation, each prepared with either Thyrogen or THW. Patients were followed up at annual clinic visits. Recurrence was defined as any evidence of (usually structural) disease identified during follow-up.2

In the ESTIMABL Study 3
Borget I, et al
(684 evaluable patients)

A significant difference in all SF-36 scores was observed between the two TSH stimulation methods at radioiodine administration (P<.001)

Mean difference in the Short Form (SF)-36 scores between random assignment and iodine administration, according to the thyroid-stimulating hormone (TSH) stimulation method.

A bar chart comparing SF-36 scores between two TSH stimulation methods during radioiodine administration.

Adapted from Borget I, et al, 2015.

ESTIMABL1 is an open-label, randomized trial involving 752 patients who underwent total thyroidectomy. All patients were randomly assigned (1:1:1:1) to 30mCi or 100mCi radioactive iodine dose, each prepared with either Thyrogen or THW. Follow-up consisted of a yearly serum thyroglobulin measurement on levothyroxine treatment. No evidence of disease was defined as serum thyroglobulin of ≤1 ng/mL on levothyroxine treatment and normal results on neck ultrasonography.3

With Thyrogen, you can help avoid some of the signs and symptoms of acute hypothyroidism by allowing your patients to remain euthyroid during ablation and diagnostic testing

In two diagnostic studies, researchers evaluated the signs and symptoms of acute hypothyroidism in two treatment arms using the Billewicz Scale.1

THYROGEN administration was not associated with the signs and symptoms of hypothyroidism that accompanied thyroid hormone withdrawal as measured by the Billewicz scale.

Statistically significant worsening in all measured signs and symptoms were observed during the acute hypothyroid phase for patients undergoing THW

A bar chart illustrating changes in signs and symptoms during the acute hypothyroid phase for patients undergoing THW.

*Higher sum indicates worsening signs and symptoms

Patient and Doctor Videos

Important Safety Information  Full Prescribing Information

Impact of Thyrogen versus Thyroid Hormone Withdrawal (THW) – A Patient’s Story

Watch Amy, a thyroid cancer patient, explain how Thyrogen (thyrotropin alfa) helps alleviate some of the signs and symptoms of hypothyroidism caused by thyroid hormone withdrawal (THW).

Important Safety InformationFull Prescribing Information

The Benefits of Thyrogen versus Thyroid Hormone Withdrawal (THW) – A Doctor’s Perspective

Watch Dr. Stephanie Lee, MD, PhD, Associate Chief, Section of Endocrinology, Nutrition and Diabetes of Boston Medical Center, share her perspective on how Thyrogen (thyrotropin alfa) helps thyroid cancer patients in preparation for radioactive iodine (RAI) ablation treatment and monitoring for progression.

Choose how to get Thyrogen® (thyrotropin alfa) for injection for your patients

Not sure which one to choose? Contact ThyrogenONE® for assistance

Desktop screen icon

Option 1: Sign up or log into the ThyrogenONE portal

The ThyrogenONE portal provides your office online access to help you and your patients:

  • Submit and track benefit verifications
  • Coordinate orders
  • Generate automatic alerts
Mobile screen icon

Option 2: Call ThyrogenONE at 1-88-THYROGEN (1-888-497-6436)

Dedicated ThyrogenONE Case Managers can assist you and your patients with the following:

  • Benefits Verification
  • Information on Ordering
  • Information on specialty pharmacy fulfillment

       

Important Safety Information

Contraindications

If Thyrogen is administered with radioiodine, the contraindications to radioiodine also apply to this combination regimen. Refer to the radioiodine prescribing information for a list of contraindications for radioiodine.

Warnings and Precautions

Thyrogen-Induced Hyperthyroidism:

  • There have been reports of death in non-thyroidectomized patients and in patients with distant metastatic thyroid cancer in which events leading to death occurred within 24 hours after administration of Thyrogen. Caution should be exercised in patients who have substantial thyroid tissue still in situ or functional thyroid cancer metastases, specifically in the elderly and those with a known history of heart disease.
  • Hospitalization for administration of Thyrogen and post-administration observation in patients at risk should be considered.

Stroke:

  • There are post marketing reports of stroke in young women with risk factors for stroke, and neurological findings suggestive of stroke (e.g., unilateral weakness) occurring within 72 hours of Thyrogen administration in patients without known central nervous system metastases. The relationship between Thyrogen administration and stroke is unknown. Patients should be well-hydrated prior to treatment with Thyrogen.

Sudden Rapid Tumor Enlargement: 

  • Sudden, rapid and painful enlargement of residual thyroid tissue or distant metastases can occur following treatment with Thyrogen. Pretreatment with glucocorticoids should be considered for patients in whom tumor expansion may compromise vital anatomic structures.

Risks Associated with Radioiodine Treatment: 

  • If Thyrogen is administered with radioiodine (RAI), the warnings and precautions for RAI apply to this combination regimen. Refer to the RAI prescribing information for a full list of the warnings and precautions for RAI.

Adverse Reactions

The most common adverse reactions reported in clinical trials were nausea and headache.

Use in Specific Populations

Pregnancy:

  • If Thyrogen is administered with radioiodine, the combination regimen is contraindicated in pregnant women.
  • Available data with Thyrogen use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Lactation:

  • The concomitant use of Thyrogen and radioiodine (RAI) is contraindicated in lactating women. If Thyrogen is administered with RAI for diagnostic use, discontinue breastfeeding after RAI administration because of the potential for serious adverse reactions from RAI in the breastfed infant.
  • If Thyrogen is not administered with RAI, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Thyrogen and any potential adverse effects on the breastfed child. There are no available data on the presence of thyrotropin alfa in human milk, the effects on the breastfed infant, or the effects on milk production.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Geriatric Use: Results from controlled trials do not indicate a difference in the safety and efficacy of Thyrogen between adult patients less than 65 years and those over 65 years of age.

Renal Impairment: Elimination of Thyrogen is significantly slower in dialysis-dependent end stage renal disease patients, resulting in prolonged elevation of TSH levels.

Indications

Thyrogen® (thyrotropin alfa) is a thyroid stimulating hormone indicated for:

Adjunctive Diagnostic Tool for Well-Differentiated Thyroid Cancer: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy.

Limitations of Use: 

  • Thyrogen-stimulated Tg levels are generally lower than, and do not correlate with Tg levels after thyroid hormone withdrawal.
  • Even when Thyrogen-Tg testing is performed in combination with radioiodine imaging, there remains a risk of missing a diagnosis of thyroid cancer or underestimating the extent of the disease.
  • Anti-Tg Antibodies may confound the Tg assay and render Tg levels uninterpretable.

Adjunct for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer: Use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.

Limitations of Use: 

  • The effect of Thyrogen on thyroid cancer recurrence greater than 5 years post-remnant ablation has not been evaluated.

Important Safety Information

Indications

References
1) Thyrogen (thyrotropin alfa for injection) Prescribing Information. Genzyme Corporation. February 2023
2) Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674-1685.
3) Borget I, Bonastre J, Catargi B, et al. Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. J Clin Oncol. 2015;33(26):2885-2892.

Thyrogen, ThyrogenONE, and Sanofi are registered trademarks of Sanofi or an affiliate. All other trademarks mentioned above are the property of their respective owners. MAT-US-2017937-v3.0-03/2025